Vnitr Lek 2019, 65(5):363-368 | DOI: 10.36290/vnl.2019.065

Multimodal treatment of thymic carcinoid: a case report

Radka Cahajlová1,*, Mária Černá1, Soňa Kiňová2
1 Oddelenie klinickej onkológie Kliniky pneumológie a funkčnej diagnostiky SZU a UNB, Nemocnica Ružinov, Bratislava, Slovenská republika
2 I. interná klinika LF UK a UNB, Nemocnica Staré Mesto, Bratislava, Slovenská republika

Thymic carcinoid account for cca 0.4 % of all carcinoid tumors in the body [1]. As compared to other neuroendocrinne tumors, high rates of reccurences after surgery, more aggressive behaviour and relatively high rates of paraneoplastic syndromes are characteristic for thymic carcinoid. The mainstay of treatment is radical surgery [2-4]. Therapy of locally advanced and metastatic stages is influenced by other neuroendocrinne tumors'guidelines. We present a case report of patient with locally advanced, atypical thymic carcinoid, treated with different modalities, including newer procedures like peptide radionuclide receptor therapy (PRRT).

Keywords: peptide radionuclide receptor therapy; somatostatine analogues; thymic carcinoid

Received: March 27, 2018; Accepted: October 5, 2018; Published: May 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cahajlová R, Černá M, Kiňová S. Multimodal treatment of thymic carcinoid: a case report. Vnitr Lek. 2019;65(5):363-368. doi: 10.36290/vnl.2019.065.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Litvak A, Pietanza MC. Bronchial and Thymic Carcinoid Tumors. Hematol Oncol Clin North Am 2016;30(1):83-102. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hoc.2015.09.003>. Go to original source... Go to PubMed...
    2. Filosso PL, Actis Dato GM, Ruffini E et al. Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): Report of a succesful case and review of the literature[online]. J Thorac Cardiovasc Surg 2004; 127(4): 1215-1219. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jtcvs.2003.09.058>. Go to original source... Go to PubMed...
    3. Mikhail M, Mekhail Y, Mekhail T Thymic neoplasm: A clinical Update [online]. Curr Oncol Rep 2012; 14(4): 350-358. Dostupné z DOI: <http://dx.doi.org/10.1007/s11912-012-0246-8>. Go to original source... Go to PubMed...
    4. Gielda BT, Peng R, Colamen JL et al. Treatment of Early stage thymic tumors: surgery and radiotion therapy. Curr Treat Options Oncol 2008; 9(4-6): 259-268. Dostupné z DOI: <http://dx.doi.org/10.1007/s11864-008-0080-2>. Go to original source... Go to PubMed...
    5. Chaer R, Massad MG, Evans A et al. Primary neuroendocrine tumors of the thymus. Ann Thorac Surg 2002; 74(5): 1733-1740. Go to original source... Go to PubMed...
    6. Öberg K, Hellman P, Ferolla P et al. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Pracstise Guidelines for diagnosis, treatment and follow up. Ann Oncol 2012; 23(Suppl 7): vii120-123. Dostupné z DOI: <http://dx.doi.org/10.1093/annonc/mds267>. Go to original source... Go to PubMed...
    7. Filosso PL, Ruffini E, Solidoro P et al. Neuroendocrine tumors of the thymus. J Thorac Dis 2017; 9(Suppl 15): S1484-S1490. Dostupné z DOI: <http://dx.doi.org/10.21037/jtd.2017.10.83>. Go to original source... Go to PubMed...
    8. Tamura M, Ohta Y, Oda M et al. Thymic carcinoid Tumor. Jpn J Thorac Cardiovasc Surg 2003; 51(1): 29-31. Dostupné z DOI: <http://dx.doi.org/10.1007/s11748-003-0063-y>. Go to original source... Go to PubMed...
    9. Srirajaskanthan R, Toubanakis C, Dusmet M et al. A review of thymic tumours. Lung Cancer 2008; 60(1): 4-13. Dostupné z DOI: <http://dx.doi.org/10.1016/j.lungcan.2008.01.014>. Go to original source... Go to PubMed...
    10. van Essen M, Krenning EP, Bakker WH et al. Peptide receptor radionuclide therapy with 177 LU-octreotate in patients with foregit carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 2007; 34(8): 1219-1227. Dostupné z DOI: <http://dx.doi.org/10.1007/s00259-006-0355-4>. Go to original source... Go to PubMed...
    11. Tomišková M. NEN plic a thymu. In: Sedláčová E, Bajčiová V (eds.) Neuroendokrinní nádory. Maxdorf: Praha 2016: 180-202. ISBN 978-80-7345-468-5
    12. Girard N. Neuroendocrine tumors of the thymus: the oncologist point of view. J Thorac Dis. 2017; 9(Suppl 15): S1491-S1500. Dostupné z DOI: <http://dx.doi.org/10.21037/jtd.2017.08.18>. Go to original source... Go to PubMed...
    13. Crona J, Björklund P, Welin S et al. Treatment, prognostic markers and survival in thymic neuroendocrine tumours. A study from a single tertiary referral centre. Lung Cancer 2013; 79(3): 289-293. Dostupné z DOI: <http://dx.doi.org/10.1016/j.lungcan.2012.12.001>. Go to original source... Go to PubMed...
    14. Song Z, Zhang Y. Primary neuroendocrine tumors of the thymus: Clinical review of 22 cases. Oncol Lett 2014; 8(5): 2125-2129. Dostupné z DOI: <http://dx.doi.org/10.3892/ol.2014.2490>. Go to original source... Go to PubMed...
    15. Dham A, Truskinovsky AM, Dudek AZ Thymic Carcinoid Responds to Neoadjuvant Therapy with Sunitinib and Octreotide. A Case report. J Thorac Oncol 2008; 3(1): 94-97. Dostupné z DOI: <http://dx.doi.org/10.1097/JTO.0b013e31815eb7a2>. Go to original source... Go to PubMed...
    16. Rinke A, Müller HH, Schade-Brittinger Cet al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009; 27(28): 4656-4663. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2009.22.8510>. Go to original source... Go to PubMed...
    17. Caplin ME, Pavel M, Cwikla JB et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371(3): 224-233. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1316158>. Go to original source... Go to PubMed...
    18. Bongiovanni A, Recine F, Riva N et al. Outcome analysis of first-line Somatostatin Analog Treatment in Metastatic pulmonary Neuroendoctrine Tumors and prognostic Significance of 18 FDG-PET/CT. Clinical Lung Cancer 2017; 18(4): 415-420. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cllc.2016.11.004>. Go to original source... Go to PubMed...
    19. Zogala D. Terapie pomocí otevřených zářičü. In: Sedláčová E, Bajčiová V (eds) Neuroendokrinní nádory. Maxdorf: Praha 2016: 156-164. ISBN 978-80-7345-468-5.
    20. Imhof A, Brunner P, Marincek N et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29(17): 2416-2423. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2010.33.7873>. Go to original source... Go to PubMed...
    21. Thapa P, Parghane R, Basu S. 177Lu-DOTATE Peptide Receptor radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of rare Sites. World J Nucl Med 201716(3):223-228. Dostupné z DOI: <http://dx.doi.org/10.4103/1450-1147.207283>. Go to original source... Go to PubMed...
    22. Puranik AD, Kulkarni HR, Singh A et al. 8-year survival with a metastatic thymic neuroendocrine tumor: emphasision redefining "treatment objectives" using personalized peptide receptor radionuclide therapy with 177LU- and 90Y-labeled somatostatin analogs. AACE Clinical Case Rep 2015; 1(2): e131-e135. Dostupné z DOI: <http://dx.doi.org/10.4158/EP14354.CR>. Go to original source...
    23. Yao JC et al. Everolimus for the treatment of advanced, on-functional neuroendorcrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-contralled, phasy 3 study. Lancet 2016; 387(10022): 968-977. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(15)00817-X>. Go to original source... Go to PubMed...
    24. Zhu S, Wang ZT, Liu WZ et al. Invasive atypical thymic carcinoid: three case reports and literature review. Onco Targets Ther 2016; 9: 6171-6176. Dostupné z DOI: <http://dx.doi.org/10.2147/OTT.S109693>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.